Earnings Call · Q4 FY2024·2025-03-27

Q4 24EPS +11.43%·Rev n/aQ3 24EPS -12.50%·Rev n/aQ2 24EPS +28.92%·Rev n/aQ1 24EPS +16.28%·Rev n/a⚠ consensus missing

RELMADA THERAPEUTICS, INC. RLMD

Brian Ritchie — Investor Relations

Sergio Traversa — CEO

Maged Shenouda — Chief Financial Officer

−2.9%1d on move date−2.6% vs SPY3d−12.0%5d−1.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RLMD calls or request research access.

More RLMD calls Browse calls Request research access